Get the Stockscreener App
30.02
0.00%
0.00
After Hours:
29.90
-0.12
-0.40%
Pharvaris Nv stock is traded at $30.02, with a volume of 547.12K.
It is up +0.00% in the last 24 hours and up +5.11% over the past month.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
See More
Previous Close:
$30.02
Open:
$30.06
24h Volume:
547.12K
Relative Volume:
2.71
Market Cap:
$1.96B
Revenue:
-
Net Income/Loss:
$-198.12M
P/E Ratio:
-8.9104
EPS:
-3.3691
Net Cash Flow:
$-159.74M
1W Performance:
+6.38%
1M Performance:
+5.11%
6M Performance:
+38.21%
1Y Performance:
+60.88%
1-Day Range:
$29.51
$30.61
1-Week Range:
$28.50
$31.14
52-Week Range:
$14.59
$31.14
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
30.02 | 1.96B | 0 | -198.12M | -159.74M | -3.3691 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Oct-15-25 | Initiated | H.C. Wainwright | Buy |
| Oct-09-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-11-25 | Initiated | Guggenheim | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-25-23 | Initiated | Wedbush | Outperform |
| Aug-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-05-22 | Initiated | Bryan Garnier | Buy |
| Sep-13-22 | Resumed | JMP Securities | Mkt Outperform |
| Aug-23-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-22-22 | Downgrade | BofA Securities | Neutral → Underperform |
| May-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Mar-02-21 | Initiated | BofA Securities | Neutral |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
View All
Pharvaris Nv Stock (PHVS) Latest News
Pharvaris Insider Sold Shares Worth $427,419, According to a Recent SEC Filing - marketscreener.com
Pharvaris (PHVS) CMO exercises $2.59 options, sells 14,166 shares under 10b5-1 plan - Stock Titan
Pharvaris N.v. Insider Sold Shares Worth $996,545, According to a Recent SEC Filing - Moomoo
Behavioral Patterns of PHVS and Institutional Flows - Stock Traders Daily
Should New Deucrictibant Data on Dual HAE Use Require Action From Pharvaris (PHVS) Investors? - Sahm
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next - AOL.com
Peng Lu Sells 15,000 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Anne Lesage Sells 3,700 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Pharvaris (NASDAQ:PHVS) Director Sells $115,168.10 in Stock - MarketBeat
Johannes Gerardus Chri Schikan Sells 29,070 Shares of Pharvaris (NASDAQ:PHVS) Stock - MarketBeat
Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 21,700 Shares of Stock - MarketBeat
Director at Pharvaris (NASDAQ: PHVS) trims stake via preset 10b5-1 sales - Stock Titan
Pharvaris (PHVS) exec Lesage sells 48K shares, exercises options - Stock Titan
Planned 18,733-share sale by Pharvaris (PHVS) chief medical officer - Stock Titan
Pharvaris (NASDAQ:PHVS) Shares Down 6%Should You Sell? - MarketBeat
Pharvaris moves closer to new preventive treatment for rare swelling disorder - MSN
Pharvaris Director Schikan Sells $213K in Shares Under Rule 10b5-1 PlanNews and Statistics - IndexBox
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighTime to Buy? - MarketBeat
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next - The Motley Fool
Pharvaris (NASDAQ:PHVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Chiesi snags on-demand HAE drug in $1.9B Kalvista buy - BioWorld News
Pharvaris N.V. (NASDAQ:PHVS) Short Interest Update - MarketBeat
PHVS Pharvaris N.V. shares climb nearly 5 percent despite fourth quarter 2025 earnings missing analyst estimates.GDR - Newser
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells 7,000 Shares of Stock - MarketBeat
Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 7,500 Shares of Stock - MarketBeat
[Form 4] Pharvaris N.V. Insider Trading Activity - Stock Titan
Pharvaris (NASDAQ:PHVS) Insider Sells $210,380.05 in Stock - MarketBeat
Pharvaris (NASDAQ:PHVS) Shares Gap Down Following Insider Selling - MarketBeat
Pharvaris (PHVS) CMO trades shares in scheduled 10b5-1 option exercise - Stock Titan
Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing - marketscreener.com
Pharvaris (NASDAQ:PHVS) Sets New 1-Year HighHere's Why - MarketBeat
(PHVS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Technical Analysis | Q4 2025: Below ExpectationsRating Upgrade - Xã Thanh Hà
[144] Pharvaris N.V. SEC Filing - Stock Titan
Is Evidence Backing Dual Deucrictibant Use Altering The Investment Case For Pharvaris (PHVS)? - Sahm
Pharvaris presents safety data on combined deucrictibant use By Investing.com - Investing.com Australia
Pharvaris N.V. (PHVS) CMO reports 226-share tax withholding event - Stock Titan
Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares but retains large stake - Stock Titan
Pharvaris says one drug may cover both HAE prevention and breakthrough attacks - Stock Titan
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighShould You Buy? - MarketBeat
Peng Lu Net Worth (2026) - GuruFocus
Anne Lesage Net Worth (2026) - GuruFocus
Pharvaris N.V. (PHVS) Presents at CIIC Spring 2026 ConferenceSlideshow (NASDAQ:PHVS) 2026-04-17 - Seeking Alpha
Pharvaris N.V. (PHVS) Stock Analysis: Exploring a 62.93% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
RBC Capital initiates coverage of Pharvaris NV (PHVS) with outperform recommendation - MSN
Affiliate files Rule 144 to sell 2,292 shares (PHVS) — prior 23,333-share 10b5-1 sale - Stock Titan
PHVS Maintained at Buy by Citigroup, April 2026 - Meyka
Pharvaris (PHVS) officer has shares withheld to cover RSU tax obligations - Stock Titan
Anna Nijdam Net Worth (2026) - GuruFocus
Pharvaris Nv Stock (PHVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):